10 Eray oo Aad U Baahan Tahay Inaad Ogaato: Kansarka Sambabka Sambabka Oo Aan Yar Yahay

Qanacsan

• Barnaamijka dhimashada-ligand 1 (PD-L1)
• Daawada cuncunka Epidermal factor receptor (EGFR)
• Isbedelka T790M
• Daaweynta Tyrosinse-kinase inhibitor (TKI)
• Isbedelka 'KRAS'
• Isbeddelidda 'lymphoma kinase' (Anaplastic lymphoma kinase (ALK) mutation)
• Adenocarcinoma
• Unugyada 'squamous cell' (epidermoid) carcinoma
• Unug weyn (aan kala sooc lahayn) carcinoma
• Immunotherapy

Guudmarka

Haddii adiga ama qofka aad jeceshahay la ogaadey, kansarka sanbabada ee unugyada yar (NSCLC) iyo ereyada badan ee laxiriira waxay noqon karaan kuwo aad u culus. Isku dayga inaad la socoto dhamaan ereyada dhakhtarkaagu kuu sheego way adkaan kartaa, gaar ahaan marka lagu daro saameynta shucuureed ee kansarka.

Waa kuwan 10 erey oo laga ogaanayo NSCLC oo laga yaabo inaad la kulanto markaad ku sii socoto baaritaanka iyo daaweynta.

Barnaamijka dhimashada-ligand 1 (PD-L1)

Tijaabinta PD-L1 waxay cabirtaa waxtarka daaweynta qaarkood ee la bartilmaameedsaday (sida caadiga ah difaaca jirka) kuwa qaba NSCLC. Tani waxay ka caawinaysaa dhakhaatiirta inay kugula taliyaan xulashooyinka daaweynta labaad ee ugu fiican.

Ku laabo bangiga ereyga

Daawada cuncunka Epidermal factor receptor (EGFR)

EGFR waa hiddo-wade ku lug leh koritaanka unugyada iyo kala qaybinta. Is-beddelka hiddo-wadahaani wuxuu la xiriiraa kansarka sanbabada. Ilaa kalabar dhammaan kiisaska kansarka sanbabada waxay leeyihiin isbeddel hidde ah.

Ku laabo bangiga ereyga

Isbedelka T790M

T790M waa isbeddel EGFR ah oo lagu arkay qiyaastii kalabar dhammaan kiisaska NSCLC ee daawooyinka u adkeysta. Isbeddelku wuxuu ka dhigan yahay inuu jiro isbeddel ku yimaad amino acids-ka, oo wuxuu saameeyaa sida qof uga jawaabi doono daaweynta.

Ku laabo bangiga ereyga

Daaweynta Tyrosinse-kinase inhibitor (TKI)

Daaweynta TKI waa nooc ka mid ah daaweynta lala bartilmaameedsaday NSCLC oo xannibaya waxqabadka EGFR, kaas oo ka ilaalin kara unugyada kansarka inay koraan.

Ku laabo bangiga ereyga

Isbedelka 'KRAS'

Hidda-wadaha KRAS wuxuu caawiyaa nidaaminta kala-qeybsanaanta unugyada. Waa qayb ka mid ah koox hiddo-wadayaal ah oo loo yaqaan 'oncogenes'. Tusaale ahaan isbeddellada, waxay u rogi kartaa unugyada caafimaadka qaba kansarro. Isbeddelada hiddo-wadaha KRAS waxaa lagu arkaa qiyaastii 15 illaa 25 boqolkiiba dhammaan kiisaska kansarka sanbabada.

Ku laabo bangiga ereyga

Isbeddelidda 'lymphoma kinase' (Anaplastic lymphoma kinase (ALK) mutation)

Isbeddelka ALK waa dib-u-habeyn hiddo-wadaha ALK ah. Isbeddelkani wuxuu ku dhacaa qiyaastii 5 boqolkiiba kiisaska NSCLC, inta badan kuwa ku jira noocyada adenocarcinoma ee NSCLC. Isbeddelku wuxuu keenaa unugyada kansarka sanbabada inay koraan oo ay faafaan.

Ku laabo bangiga ereyga

Adenocarcinoma

Adenocarcinoma waa nooc ka mid ah NSCLC. Waxay u egtahay inay ka gaabiso noocyada kale ee kansarka sanbabada, laakiin tani way kala duwan tahay. Waa nooca ugu badan ee kansarka sanbabada ee lagu arko dadka aan sigaarka cabbin.

Ku laabo bangiga ereyga

Unugyada 'squamous cell' (epidermoid) carcinoma

Kansarka unugyada 'squamous cell carcinoma' waa nooc hoosaad ah NSCLC. Dad badan oo qaba noocan ah kansarka sanbabada waxay leeyihiin taariikh sigaar. Kansarku wuxuu ka bilaabmaa unugyada squamous, kuwaas oo ah unugyo ku dhexyaal hawo mareenka sambabka.

Ku laabo bangiga ereyga

Unug weyn (aan kala sooc lahayn) carcinoma

Kansarka weyn ee unugyada waa nooc ka mid ah NSCLC oo ka muuqan kara qayb kasta oo ka mid ah sanbabada. Caadi ahaan way adagtahay in la daweeyo maxaa yeelay way koreysaa oo dhaqso ayey u faaftaa. Waxay ku saabsan tahay 10 ilaa 15 boqolkiiba kansarrada sanbabada.

Ku laabo bangiga ereyga

Immunotherapy

Immunotherapy waa daaweyn cusub oo loogu talagalay kansarka oo isticmaala nidaamka difaaca jirka si uu uga caawiyo jirka inuu weeraro unugyada kansarka. Waxaa loo isticmaali karaa in lagu daaweeyo noocyo ka mid ah NSCLC, gaar ahaan dadka kansarkoodu soo noqday ka dib daaweynta kiimoterabiga ama daaweyn kale.

Ku laabo bangiga ereyga